Phase 2 I’ve written previously about how expensive clinical trials are, and how not many companies are actually cashed enough to run the trials they plan on. Companies need…
shroom boom 2021
Biting the hand that feeds you Nova Mentis Life Sciences (NOVA.C) director Steven Feldman has some interesting thoughts around vaccines, and as a life sciences company, I think it’s…
Debt is good, sometimes Debt is an important factor when sussing out a company to invest in. Knowing why the company has taken out debt, how much debt they’ve…
Data protection Earlier this week a federal review echoed The Canadian Ministry of Health’s original decision to deny data protection for Johnson & Johnson (JNJ.Q)’s Spravato product, a ketamine-derived…
Death & children’s novels When I think about Amanita Muscaria the first two things that come to mind are death, and children’s novels. Amanita Muscaria is arguably the…
90% There are a lot of newer investors interested in psychedelics, which is great. But, there are some pretty big pitfalls to watch out for out there. It’s important…
Psytech Wesana Health (WESA.CN) announced a big change to its business plan earlier this week. They are acquiring Psytek Inc. for $21M CAD in Wesana stock. The acquisition of…
In the cannabis sector, there is a wide net of different types of companies from growers to extractors to logistics & tech and everything in-between. In the earlier days…